Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.

Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators

Open source

DOI
10.1016/s0140-6736(22)01787-1
Published
2022 Oct 22
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-22-01787-1,
  title = {Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.},
  author = {Bhatt DL and Vaduganathan M and Kandzari DE and Leon MB and Rocha-Singh K and Townsend RR and Katzen BT and Oparil S and Brar S and DeBruin V and Fahy M and Bakris GL and SYMPLICITY HTN-3 Steering Committee Investigators},
  year = {2022},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(22)01787-1},
  url = {https://doi.org/10.1016/s0140-6736(22)01787-1}
}

RIS

TY  - JOUR
TI  - Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
AU  - Bhatt DL
AU  - Vaduganathan M
AU  - Kandzari DE
AU  - Leon MB
AU  - Rocha-Singh K
AU  - Townsend RR
AU  - Katzen BT
AU  - Oparil S
AU  - Brar S
AU  - DeBruin V
AU  - Fahy M
AU  - Bakris GL
AU  - SYMPLICITY HTN-3 Steering Committee Investigators
PY  - 2022
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(22)01787-1
UR  - https://doi.org/10.1016/s0140-6736(22)01787-1
ER  - 

APA

DL, B., M, V., DE, K., MB, L., K, R., RR, T., BT, K., S, O., S, B., V, D., M, F., GL, B., & Investigators, S. H. S. C. (2022). Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(22)01787-1

Source records